Breaking News: Myriad Genetics Acquires Gateway Genomics | Learn More
Fill in your information below and we’ll send you an email with more information
MyRisk with RiskScore is a powerful tool that evaluates 48 genes associated with 11 different hereditary cancers. More than a test, it’s the foundation for personalized care plans you can use to make confident decisions and help improve patient outcomes.
Knowing your patients’ hereditary cancer risk can dramatically impact the medical management decisions you make today.
MyRisk results, whether negative, positive or elevated, can be used to your patients’ benefit. Combined with their cancer family history, the report will provide you with valuable information to effectively make decisions and manage patient cancer risk on an individual basis.
1DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
Meet Katya, an ovarian cancer survivor, BRCA1 mutation carrier and mother of three. Hear how MyRisk testing empowered her and her family to take control of their health.
Most hereditary cancer tests only produce positive or negative results. MyRisk takes this a step further, including the MyRisk Management Tool in every report. This easy-to-use guide breaks down everything you need to know about using these results to inform your patient’s personal care plan today and in the future.
When it comes to assessing breast cancer risk, MyRisk goes a step further by giving patients who receive a negative test result a RiskScore®.
RiskScore is a component of the MyRisk test that provides a personalized estimate of a person’s likelihood to develop breast cancer over the next 5 years and their lifetime, guiding patients and providers to make more confident and informed medical decisions for managing breast cancer risk.
As the only hereditary cancer test designed for patients of all ancestries, MyRisk with RiskScore helps you give more patients answers about their cancer risks than ever before.
56%2 of patients tested with MyRisk qualify for a change in their medical management vs. approximately 10% expected if tested with other labs.
2Myriad Internal Data based on OBGYN and Primary Care Settings, Sept 2019
Integrating MyRisk into your practice has never been easier with second-to-none expert support and the MyRisk Management Tool that simplifies reading and implementing results.
We support patients and healthcare providers throughout the genetic testing process through pre-test education, transparent pricing, billing support, clear results reporting, and post-test education.
These services allow for simple integration of Myriad Genetics’s tests into routine clinical care and help patients better understand and benefit from their results.